The KNDC1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population designed to disrupt the KNDC1 tumor suppressor gene. This heterogeneous pool contains diverse loss-of-function mutations, providing a robust model for quantitative signaling and functional assays without the biases of clonal selection. It enables systematic investigation of KNDC1??s role as a negative regulator of the RAS-MAPK pathway in a cancer cell context.
HeLa cells, derived from a human cervical adenocarcinoma, serve as the host line. These immortalized epithelial cells are highly tractable for genome editing, with well-characterized signaling pathways and high transfection efficiency, making them a workhorse for molecular oncology studies. However, their HPV-driven transformation and complex genomic landscape must be considered when interpreting tumor suppressor gene behavior, making them a physiologically relevant yet experimentally convenient model for KNDC1 studies.
KNDC1 encodes a pseudokinase that functions as a negative regulator of RAS-MAPK signaling by directly interacting with RAS GTPases (KRAS, HRAS, NRAS). This interaction inhibits downstream RAF-MEK-ERK cascade activation, suppressing ERK1/2 phosphorylation and cell proliferation. KNDC1 acts downstream of EGFR signaling and RAS activation, and its disruption removes a critical brake on mitogenic signaling, entailing potential implications for oncogenic processes, particularly in tissues with high EGFR-RAS pathway activity.
In the HeLa background, where E6/E7 oncoproteins from HPV elevate basal MAPK pathway activity, KNDC1 knockout further potentiates ERK signaling. This model recreates a tumor-suppressive gene loss scenario in an already transformed cervical epithelial context, allowing the study of cooperative oncogenic mechanisms. It is particularly suited to examine how KNDC1 constraints on RAS-MAPK output influence proliferation, survival, and therapeutic response in cervical cancer, a malignancy with limited targeted treatment options.
Typical applications include phospho-ERK western blotting, RAS activity assays, cell proliferation and colony formation assays, and drug response profiling. This polyclonal knockout pool supports research into cancer cell signaling, tumor suppressor validation, and drug target identification, enabling comprehensive functional analysis of KNDC1??s role in oncogenic signaling. For technical inquiries or custom services, contact Ascent Research.
